Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention
- PMID: 16246055
- DOI: 10.1042/BST20051101
Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention
Abstract
The accumulation of Abeta (amyloid beta-protein) peptides in the brain is a pathological hallmark of all forms of AD (Alzheimer's disease) and reducing Abeta levels can prevent or reverse cognitive deficits in mouse models of the disease. Abeta is produced continuously and its concentration is determined in part by the activities of several degradative enzymes, including NEP (neprilysin), IDE (insulin-degrading enzyme), ECE-1 (endothelin-converting enzyme 1) and ECE-2, and probably plasmin. Decreased activity of any of these enzymes due to genetic mutation, or age- or disease-related alterations in gene expression or proteolytic activity, may increase the risk for AD. Conversely, increased expression of these enzymes may confer a protective effect. Increasing Abeta degradation through gene therapy, transcriptional activation or even pharmacological activation of the Abeta-degrading enzymes represents a novel therapeutic strategy for the treatment of AD that is currently being evaluated in cell-culture and animal models. In this paper, we will review the roles of NEP, IDE, ECE and plasmin in determining endogenous Abeta concentration, highlighting recent results concerning the regulation of these enzymes and their potential as therapeutic targets.
Similar articles
-
Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.Neurobiol Aging. 2005 May;26(5):645-54. doi: 10.1016/j.neurobiolaging.2004.06.013. Neurobiol Aging. 2005. PMID: 15708439
-
Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology.Neurosci Lett. 2008 Jun 20;438(2):216-20. doi: 10.1016/j.neulet.2008.04.025. Epub 2008 Apr 12. Neurosci Lett. 2008. PMID: 18455870
-
Aβ-degrading enzymes: potential for treatment of Alzheimer disease.J Neuropathol Exp Neurol. 2011 Nov;70(11):944-59. doi: 10.1097/NEN.0b013e3182345e46. J Neuropathol Exp Neurol. 2011. PMID: 22002425 Review.
-
Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.Med Hypotheses. 2006;67(4):682-97. doi: 10.1016/j.mehy.2006.04.067. Epub 2006 Jul 7. Med Hypotheses. 2006. PMID: 16828233
-
Metabolism of amyloid-beta peptide and Alzheimer's disease.Pharmacol Ther. 2005 Nov;108(2):129-48. doi: 10.1016/j.pharmthera.2005.03.010. Epub 2005 Aug 19. Pharmacol Ther. 2005. PMID: 16112736 Review.
Cited by
-
Linking type 2 diabetes and Alzheimer's disease.Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6557-8. doi: 10.1073/pnas.1002555107. Epub 2010 Apr 12. Proc Natl Acad Sci U S A. 2010. PMID: 20385830 Free PMC article. No abstract available.
-
Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways.J Alzheimers Dis. 2019;68(2):657-668. doi: 10.3233/JAD-180906. J Alzheimers Dis. 2019. PMID: 30775986 Free PMC article.
-
Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells.J Alzheimers Dis. 2009;17(3):489-501. doi: 10.3233/JAD-2009-1066. J Alzheimers Dis. 2009. PMID: 19363254 Free PMC article.
-
Chronic treatment with anesthetic propofol attenuates β-amyloid protein levels in brain tissues of aged mice.Transl Neurodegener. 2014 Apr 11;3(1):8. doi: 10.1186/2047-9158-3-8. Transl Neurodegener. 2014. PMID: 24725331 Free PMC article.
-
Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathology.PLoS One. 2014 May 20;9(5):e98057. doi: 10.1371/journal.pone.0098057. eCollection 2014. PLoS One. 2014. PMID: 24846272 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical